Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Grow...(in % of net sales 12.8 ...)

Date:2/17/2009

in % of net sales 12.8 12.2 Profit from operations (EBIT) 61.0 53.3 +14.4 Net income 4.5 0.8 >100 Adjusted net income(2) 61.4 44.3 +38.6 Earnings per share in EUR 0.02 -0.04 >100 Adjusted earnings per 1.83 1.34 +36.6 share(3) in EUR --------------------------------- (1) Adjusted EBITDA: earnings before income taxes, financial result, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses (2) Adjusted net income: consolidated profit before non-cash amortization of fair value adjustments, special effects from restructuring expenses, extraordinary depreciation, the balance of one-off income and expenses (including significant non-cash expenses) and the related tax effects (3) Adjusted net income after minorities divided by 31.4m shares Contact Press Burkhard Lingenberg Director Corporate Communication & Marketing Phone +49-211-6181-250 Fax +49-211-6181-241 e-mail b.lingenberg@gerresheimer.com Contact Investor Relations Anke Linnartz Director Corporate Investor Relations Phone +49-211-6181-314 Fax +49-211-6181-121 e-mail a.linnartz@gerresheimer.com
'/>"/>

SOURCE Gerresheimer AG Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
11. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results